David Moadel

David Moadel

Expertise: Stocks, Options, Precious metals, Bitcoin, Altcoins

Education: Master's degree in education from the American College of Education, Bachelor's degree in education from Florida Atlantic University, Associate's degree in liberal arts from Palm Beach Community College

About David:
David Moadel is a financial writer for InvestorPlace.com. He has a master’s degree in education and has authored financial content for multiple websites.

David is also active as a social media influencer, with tens of thousands of followers on YouTube, Twitter, StockTwits, and other popular sites. David writes on topics ranging from stocks to cryptocurrencies, options, precious metals, bonds, futures, and other areas of finance.

Focusing on data rather than emotions, David is always on the lookout for new pathways to financial freedom. Count on David for wealth-building strategies and resources for investors and traders of all financial backgrounds.

You can follow David on YouTube, Twitter, StockTwits and LinkedIn.

Recent Articles

Add Gevo Stock to Your Sustainability-Focused Holdings Once Prices Lower

GEVO stock is down from its peak price, and this may catch value investors' attention. Yet, the data appears to signal a need for caution.

Sundial Growers Is Bound to Be a Surprise Summer Hit

SNDL stock went from a meme favorite to a forgotten treasure in the cannabis space. The stock's decline presents an opportunity.

Invest in Growth-Oriented Tech with Invesco QQQ ETF

Whether for a short-term trade or a long-term investment, you can position yourself quickly in the technology sector with QQQ stock.

Bull Thesis for Workhorse Group Is That Things Can’t Get Much Worse

The fiscal results are in and they're quite grim - yet, contrarians may find an opportunity in the negative sentiment surrounding WKHS stock.

Target Highly Promising Antiviral Therapeutics with Cocrystal Pharma

A buying opportunity is here as COCP stock is down, even as Cocrystal makes progress in developing a potentially lifesaving antiviral drug.

Hold Off On TPG Pace Beneficial Finance as Deal Risk Persists

Even promising SPAC deals can fall through. This is a risk TPGY stock holders must deal with - or they can just bail and avoid this problem.

With New CEO’s 5G Focus and Beat-Down Price, Qualcomm Stock Is a Buy Here

Soon, Qualcomm will have a new CEO. Transitions can be challenging, but QCOM stock investors should maintain an optimistic outlook.

Disney Is Still a Terrific Investment Despite Missing Subscriber Estimates

Some investors might consider dumping their DIS stock shares due to concerns over Disney's steaming service, but the fears may be overblown.

Hold Microsoft Stock as Its Meme-Worthy Browser Is Finally Put to Rest

As the company unplugs a browser that's been around since 1995, MSFT stock holders should appreciate Microsoft's willingness to move forward.

Another Short Squeeze Appears to Be Brewing for GameStop

After the previous GME stock short squeeze, traders learned to take social media more seriously - and another big move could be in the works.